ArticleDermatology and therapy2022
Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry.
Benjamin Lockshin et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
6 papers cite it
this paperpooled itcites it